

## Quarterly activities report for April – June 2022

The quarterly activities include details of monitoring and compliance activities by the Office of the Gene Technology Regulator (OGTR) during the quarter.

### Monitoring of GMO Dealings involving Intentional Release (DIR)

During the quarter the OGTR inspected **four GM plant field trial sites (Table 1)**.

- Current field trial sites - of the **nine** sites current in the quarter, **one** was inspected.
- Post-harvest field trial sites - of the **12** sites subject to post-harvest monitoring in the quarter, **three** were inspected.
- The sites inspected in Queensland were visited in response to an extreme weather event.

Table 1 – Summary of inspection activities of GM crop field trials for the April – June 2022 quarter.

Licence Holder	Licence Number	GM Crop	Site location (crop status <sup>1</sup> )
The University of Adelaide	DIR 186	Wheat	SA (1 C)
The University of Queensland	DIR 153	Sorghum	Qld (3 PH)
<b>Total</b>			<b>4</b>

### Monitoring of GMO Dealings Not involving Intentional Release (DNIR), certified facilities and DIR clinical and veterinary trials

During the quarter, the OGTR inspected **four** organisations holding certified facilities (**Table 2**) and **one** DIR veterinary trial (**Table 3**).

Table 2 – Summary of organisations and facility types that the OGTR inspected for the April – June 2022 quarter.

Organisation	Physical Containment (PC) level	Number of facilities monitored
CSIRO	PC2 Animal Facility	4
DST Group Melbourne	PC2 Laboratory	1
Bioproperties Pty Ltd	PC2 Laboratory	5
	PC2 Large Scale	2
University of Wollongong	PC2 Laboratory	3
<b>Total</b>		<b>15</b>

<sup>1</sup> PH = post-harvest site; C = current site

Table 3 – Summary of inspection activities for DNIR licences and DIR clinical and veterinary trial licences for the January – March 2022 quarter.

<b>Licence holder</b>	<b>Licence number</b>
Bioproperties Pty Ltd	DIR 154

### **Practice Reviews, Audits and Investigations**

The Monitoring and Compliance section may initiate practice reviews in response to observations made during earlier monitoring activities, or to follow up incident reports or to assess the effectiveness of systems used by licence holders and IBC(s). The objective is to determine if licence conditions can be, and are being, effectively implemented. No practice reviews or investigations were undertaken during the quarter.

During the April – June 2022 quarter the OGTR initiated an audit of University of Adelaide in South Australia and the findings will be reported in the Regulator’s Annual Report.

### **Other activities**

During the April-June 2022 quarter the Monitoring and Compliance section attended the 10<sup>th</sup> Annual ABSANZ Biosafety and Biocontainment Conference.

### **Monitoring and Compliance Findings**

Findings from routine monitoring, auditing and investigations, and related enforcement activities, are provided in the Regulator’s Annual Report in accordance with section 136 of the *Gene Technology Act 2000*.